Ammalife is pleased to announce our partnership with clinical products supplier, Kimal, whose Ammalife PPH Detection Drape will ensure women are rapidly diagnosed if they lose too much blood during birth.
Postpartum haemorrhage (PPH) is the most common reason for death related to childbirth globally. Every day, 200 mothers will die from PPH. It can be difficult to assess bleeding and decide when blood loss reaches dangerous levels. If PPH isn’t detected accurately, treatment can come to late or too slow. At best, the delay could mean a woman is too sick to nurse well, at worst is can lead to surgery like hysterectomy or to death.
In 2023, the E-MOTIVE trial was published in the prestigious journal NEJM. The study, which recruited over 210,000 women across countries where deaths and poor maternal health from PPH are high, tested the use of the blood collection drape to aid in PPH detection, alongside a bundle of treatments (called ‘MOTIVE’) that could be rapidly deployed once a potentially dangerous bleed was detected. The result was phenomenal. Early detection (‘E’) combined with a bundle of treatment that was already recommended by the WHO (‘MOTIVE’) reduced the most serious bleeds and worst outcomes of PPH by 60%.
Ammalife was a key partner in the E-MOTIVE trial and helped to ensure that all of the ‘control’ sites which did not receive the drape during the study were able to access this lifesaving intervention as soon as it’s impact was known.
The Ammalife PPH Detection drape, designed by Kimal
Kimal have manufactured innovative clinical products for many years, and when they heard about the drape, they contacted the E-MOTIVE and Ammalife teams to find out what they could learn. The outcome of this is the ‘Ammalife PPH Detection Drape’, designed using expertise from the groundbreaking E-MOTIVE study, but also with insights from UK clinical teams to create a product that would be acceptable to women and suitable for use in different clinical settings.
“We saw an opportunity to address a clear clinical need with a simple, practical, evidence-based product” said Stacey Tyler, Maternity Business Unit Manager for Kimal. “When a woman is bleeding after birth, clinicians need clear information to help them recognise excessive blood loss and respond. The drape is designed to support exactly that”. Kimal is manufacturing the Ammalife PPH Detection Drape for use across Europe, the Middle East and Asia, where the E-MOTIVE interventions have not yet been rolled out and drape use is still uncommon. Several NHS trusts across the UK have already come on board. Kimal pledged a donation to Ammalife with every drape sold in the UK and as of September 2026, we have begun to receive donations. Given that objective measurement of blood loss has recently been recommended for all UK births, this partnership could make a huge impact on Ammalife and the work we can do to tackle poor maternal health globally.
On behalf of Kimal, Stacey Tyler said “We believe every woman deserves to give birth safely, wherever she lives. That’s why we’re proud to support Ammalife and its work to make that a reality for more women and their families. By bringing our manufacturing and commercial experience together with Ammalife’s research and clinical expertise, we can help make a practical, evidence-based product more widely available. It’s a partnership that puts our shared commitment to safer maternity care into practice.”
Ammalife’s Chair of Trustees, Imran Pasha, has celebrated this collaboration as a significant moment for Ammalife: “Our partnership with Kimal brings together maternal health expertise, evidence led innovation and the ability to put practical solutions into the hands of clinicians. For Ammalife, the partnership provides an important route to translate research into real world impact, such as supporting safer maternity care within the NHS while also helping make effective, affordable solutions available to women in lower resource settings around the world.”
Leave A Comment